Holen Sie sich die Stockscreener-App
22.20
0.14%
0.03
Vorhandelsmarkt:
22.20
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Sarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says - marketscreener.com
United States Gene Therapy Market to Hit $6510.45 Million by 2033 - openPR.com
Sarepta Therapeutics (NASDAQ:SRPT) Nasdaq Index Tracks Biotech Advancements - Kalkine Media
Sarepta Therapeutics (SRPT): Reassessing Valuation After a Sharp One-Month Share Price Rebound - Yahoo Finance
Is Sarepta Therapeutics a Bargain After Recent Share Rebound and DCF Valuation Check? - Yahoo Finance
Sarepta Therapeutics Gets A Vote Of Confidence After Sell-Off - Finimize
Wedbush Says Sarepta Selloff “Overdone” - GuruFocus
Sarepta Offers 'Attractive' Entry Point After Setbacks, Wedbush Says - marketscreener.com
Sarepta Therapeutics (SRPT) Rated Outperform by Wedbush with 46% Upside Potential - GuruFocus
Sarepta a new outperform at Wedbush as selloff overdone - Seeking Alpha
Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated by Analysts at Wedbush - MarketBeat
SRPT: Wedbush Initiates Coverage with Outperform Rating | SRPT S - GuruFocus
Wedbush initiates Sarepta Therapeutics stock coverage with Outperform rating By Investing.com - Investing.com UK
Sarepta (SRPT) Stock Outlook: Wedbush Predicts Potential Growth - GuruFocus
Regenerative Medicine Market 2025-2033: Key Trends, Research - openPR.com
New York State Common Retirement Fund Sells 7,923,000 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Norges Bank Buys Shares of 913,407 Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Dyne Readies DMD Exon-Skipper For Filing, Could Be Competitive With Sarepta Drug - Citeline News & Insights
Why Is Dyne Therapeutics Stock Surging Monday?Dyne Therapeutics (NASDAQ:DYN), Sarepta Therapeutics (NASDAQ:SRPT) - Benzinga
Sarepta Therapeutics grants $12 million equity award to CEO Douglas Ingram - Investing.com India
Sarepta Therapeutics grants $12 million equity award to CEO Douglas Ingram By Investing.com - Investing.com South Africa
Sarepta Grants CEO Equity Awards After Eight Years - TipRanks
Sarepta Therapeutics Inc Stock Baskets - GuruFocus
Sarepta Therapeutics Inc Stock Operating Data - GuruFocus
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 26% But Its Business Still Trails The Industry - 富途牛牛
With Sarepta Therapeutics Stock Surging, Have You Considered The Downside? - Trefis
Technical Reactions to SRPT Trends in Macro Strategies - news.stocktradersdaily.com
Sarepta Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Edgestream Partners L.P. Purchases 74,427 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Is Sarepta Therapeutics Stock Built to Withstand a Pullback? - Trefis
How Sarepta Therapeutics Inc. (AB3A) stock expands through international marketsWeekly Trade Analysis & Safe Swing Trade Setups - Newser
Is Sarepta Therapeutics Inc. (AB3A) stock suitable for passive index fundsMarket Rally & Fast Exit Strategy with Risk Control - Newser
Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst - Benzinga
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap DownTime to Sell? - MarketBeat
There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise - simplywall.st
How Sarepta Therapeutics Inc. stock performs in weak economy2025 Valuation Update & Safe Capital Growth Stock Tips - Newser
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report? - Yahoo Finance
Why Sarepta Therapeutics Inc. (AB3A) stock is upgraded to buyInsider Selling & Stock Portfolio Risk Management - Newser
Will Sarepta Therapeutics Inc. (AB3A) stock test record highs in 2025Portfolio Update Report & Free Daily Entry Point Trade Alerts - Newser
Did FDA Green Light for ELEVIDYS and Pipeline Progress Just Shift Sarepta Therapeutics' (SRPT) Narrative? - simplywall.st
Sarepta's Duchenne gene therapy misses main goal in late-stage study; shares fall - MSN
Sarepta’s Elevidys: Boxed Warning On Cardiotoxicity Events Not Needed, US FDA Says - Citeline News & Insights
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys - MSN
SRPT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sarepta Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Sarepta Therapeutics, Inc. (SRPT) Options Chain - Yahoo! Finance Canada
Sarepta Therapeutics (SRPT): Evaluating Valuation After FDA Progress and Pipeline Milestones - simplywall.st
Geode Capital Management LLC Raises Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
FY2025 EPS Estimate for Sarepta Therapeutics Cut by Analyst - MarketBeat
Envestnet Asset Management Inc. Decreases Stake in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
How Do Sarepta (SRPT)’s Enhanced Safety Moves Reflect Its Approach to Long-Term Risk Management? - Yahoo Finance
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 8.3%Still a Buy? - MarketBeat
Is Sarepta Therapeutics a Bargain After FDA Approval and Last Week's 27.8% Rally? - simplywall.st
Sarepta Therapeutics (SRPT) Gets a Buy from Wells Fargo - The Globe and Mail
Why analysts raise outlook for Sarepta Therapeutics Inc. (AB3A) stockJuly 2025 Action & Entry Point Confirmation Alerts - BỘ NỘI VỤ
Sarepta (SRPT) gets FDA approval on new gene therapy study - Investorsobserver
KBC Group NV Cuts Stake in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo Finance
Tech Stocks Surge Ahead Of Thanksgiving, Robinhood Rallies 10%: What's Moving Markets Wednesday? - Benzinga
Sarepta cleared to test new safety regimen for Duchenne drug - statnews.com
Sarepta to investigate immunosuppressant Elevidys combo to avoid fatal AEs - Yahoo
Sell Rating for Sarepta Therapeutics Due to Risks in ENDEAVOR Study and Expected Share Price Decline - TipRanks
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):